MetaStat holds a performance score of 12 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -0.9, which conveys possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning MetaStat are expected to decrease slowly. On the other hand, during market turmoil, MetaStat is expected to outperform it slightly. Use MetaStat total risk alpha and day median price , to analyze future returns on MetaStat.
Risk-Adjusted Performance
Good
Weak
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in MetaStat are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, MetaStat unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Begin Period Cash Flow
782.7 K
Total Cashflows From Investing Activities
-30.1 K
MetaStat
MetaStat Relative Risk vs. Return Landscape
If you would invest 0.02 in MetaStat on September 28, 2025 and sell it today you would earn a total of 0.05 from holding MetaStat or generate 250.0% return on investment over 90 days. MetaStat is currently generating 2.8205% in daily expected returns and assumes 17.5716% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than MetaStat, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
Expected Return
Risk
Given the investment horizon of 90 days MetaStat is expected to generate 24.67 times more return on investment than the market. However, the company is 24.67 times more volatile than its market benchmark. It trades about 0.16 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.12 per unit of risk.
MetaStat Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MetaStat's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as MetaStat, and traders can use it to determine the average amount a MetaStat's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1605
Best Portfolio
Best Equity
Good Returns
MTST
Average Returns
Small Returns
Cash
Small Risk
Average Risk
High Risk
Huge Risk
Negative Returns
Based on monthly moving average MetaStat is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MetaStat by adding it to a well-diversified portfolio.
MetaStat Fundamentals Growth
MetaStat Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of MetaStat, and MetaStat fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MetaStat Pink Sheet performance.
Assessing MetaStat's fundamental ratios provides investors with valuable insights into MetaStat's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the MetaStat is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The companys therapeutic targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. MICROTEST INC operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people.
Things to note about MetaStat performance evaluation
Checking the ongoing alerts about MetaStat for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for MetaStat help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
MetaStat has some characteristics of a very speculative penny stock
MetaStat appears to be risky and price may revert if volatility continues
MetaStat has high likelihood to experience some financial distress in the next 2 years
MetaStat has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
MetaStat currently holds 1000 K in liabilities with Debt to Equity (D/E) ratio of 839.5, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. MetaStat has a current ratio of 0.16, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist MetaStat until it has trouble settling it off, either with new capital or with free cash flow. So, MetaStat's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like MetaStat sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for MetaStat to invest in growth at high rates of return. When we think about MetaStat's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 23.3 K. Net Loss for the year was (3.18 M) with loss before overhead, payroll, taxes, and interest of (1.23 M).
MetaStat currently holds about 316.93 K in cash with (2.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Evaluating MetaStat's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate MetaStat's pink sheet performance include:
Analyzing MetaStat's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MetaStat's stock is overvalued or undervalued compared to its peers.
Examining MetaStat's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating MetaStat's management team can have a significant impact on its success or failure. Reviewing the track record and experience of MetaStat's management team can help you assess the Company's leadership.
Pay attention to analyst opinions and ratings of MetaStat's pink sheet. These opinions can provide insight into MetaStat's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating MetaStat's pink sheet performance is not an exact science, and many factors can impact MetaStat's pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Additional Tools for MetaStat Pink Sheet Analysis
When running MetaStat's price analysis, check to measure MetaStat's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MetaStat is operating at the current time. Most of MetaStat's value examination focuses on studying past and present price action to predict the probability of MetaStat's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MetaStat's price. Additionally, you may evaluate how the addition of MetaStat to your portfolios can decrease your overall portfolio volatility.